RxDoctor Payments Data

Ronald Davidoff, MD

Child & Adolescent Psychiatry · Enfield, CTNPI 1447366455

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 25 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 9 manufacturers reported payments, led by Neurocrine Biosciences, Inc. at 36.0% of the total.

$460in general payments, 2019–2025

Across 25 payments — averaging $18.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Neurocrine Biosciences, Inc.$166
  • Otsuka America Pharmaceutical, Inc.$63
  • Sunovion Pharmaceuticals Inc.$62
  • Shire North American Group Inc$47
  • AbbVie$31
  • Johnson & Johnson$30
  • plus $61 from 3 others

What the payments were for

  • Food & beverage$460100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$460 in reported general payments places this provider in the 70th percentile of 71 child & adolescent psychiatry providers in Connecticut.

See all child & adolescent psychiatry providers in Connecticut

Medicare billing

Part B allowed, 2024
$5,282
Medicare patients
20
Services billed
66

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Lurasidone Hcl48$40,902
VraylarCariprazine Hcl11$15,305
LamictalLamotrigine24$8,502
Aripiprazole74$7,156
Bupropion XlBupropion Hcl113$2,341
Risperidone66$2,134
Duloxetine Hcl63$1,943
Clozapine13$1,841
Lorazepam167$1,728
Clonazepam164$1,710
Quetiapine Fumarate ErQuetiapine Fumarate27$1,470
Trazodone Hcl111$1,457
Sertraline Hcl55$1,253
Perphenazine22$1,247
Fluoxetine Hcl109$1,219

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieVraylar$31$15,30511 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 71 child & adolescent psychiatry providers in Connecticut.

Other child & adolescent psychiatry in Enfield

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →